Cellavision Q3’23: Normalization in progress

Research Update

2023-10-26

07:00

Redeye’s view on the Q3 report. The organic growth trend turned positive with improvement in APAC and continued positive development in the Americas. The gross margin and OPEX levels created a negative deviation from our results expectations while the cash flow was strong. We have made minor changes to our estimates and increased the WACC due to a higher risk-free interest rate. We thus slightly downward adjust our Base case to SEK 221 (230) and fair value range to SEK 150 – 360 (160 – 380) per share.

MH

Mats Hyttinge

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.